In castration-resistant prostate cancer (CRPC), the SREBP2 is activated by PTEN/p53 deficiency, thereby upregulating cholesterol metabolism and facilitating tumor cell survival and growth (Shangguan et al., 2022). Here, SREBF2 is linked to neoplasm.